Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Research review: Cholinergic mechanisms, early brain development, and risk for schizophrenia.

Ross RG, Stevens KE, Proctor WR, Leonard S, Kisley MA, Hunter SK, Freedman R, Adams CE.

J Child Psychol Psychiatry. 2010 May;51(5):535-49. doi: 10.1111/j.1469-7610.2009.02187.x. Epub 2009 Nov 18. Review.

2.

Perinatal choline effects on neonatal pathophysiology related to later schizophrenia risk.

Ross RG, Hunter SK, McCarthy L, Beuler J, Hutchison AK, Wagner BD, Leonard S, Stevens KE, Freedman R.

Am J Psychiatry. 2013 Mar;170(3):290-8. doi: 10.1176/appi.ajp.2012.12070940. Erratum in: Am J Psychiatry. 2013 May 1;170(5):566.

3.

Maximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits.

Stevens KE, Zheng L, Floyd KL, Stitzel JA.

Brain Res. 2015 Jun 22;1611:8-17. doi: 10.1016/j.brainres.2015.02.044. Epub 2015 Mar 2.

4.

Schizophrenia and the alpha7 nicotinic acetylcholine receptor.

Martin LF, Freedman R.

Int Rev Neurobiol. 2007;78:225-46. Review.

PMID:
17349863
5.

Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.

Zhang XY, Liu L, Liu S, Hong X, Chen DC, Xiu MH, Yang FD, Zhang Z, Zhang X, Kosten TA, Kosten TR.

Am J Psychiatry. 2012 Sep;169(9):974-81. doi: 10.1176/appi.ajp.2012.11081289.

PMID:
22952075
6.

Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Olincy A, Stevens KE.

Biochem Pharmacol. 2007 Oct 15;74(8):1192-201. Epub 2007 Jul 17. Review.

7.

Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism.

Wildeboer KM, Zheng L, Choo KS, Stevens KE.

Brain Res. 2009 Dec 1;1300:41-50. doi: 10.1016/j.brainres.2009.08.075. Epub 2009 Sep 1.

8.

Schizophrenia, sensory gating, and nicotinic receptors.

Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R.

Schizophr Bull. 1998;24(2):189-202. Review.

PMID:
9613620
9.

Sustained increase of alpha7 nicotinic receptors and choline-induced improvement of learning deficit in STOP knock-out mice.

Bouvrais-Veret C, Weiss S, Andrieux A, Schweitzer A, McIntosh JM, Job D, Giros B, Martres MP.

Neuropharmacology. 2007 Jun;52(8):1691-700. Epub 2007 Apr 14.

10.

Evidence for gamma and beta sensory gating deficits as translational endophenotypes for schizophrenia.

Smucny J, Wylie K, Rojas D, Stevens K, Olincy A, Kronberg E, Zheng L, Tregellas J.

Psychiatry Res. 2013 Nov 30;214(2):169-74. doi: 10.1016/j.pscychresns.2013.07.002. Epub 2013 Aug 21.

11.

α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia.

Ishikawa M, Hashimoto K.

Curr Pharm Des. 2011;17(2):121-9. Review.

PMID:
21355839
12.

Therapeutic implications of a selective alpha7 nicotinic receptor abnormality in schizophrenia.

Deutsch SI, Rosse RB, Schwartz BL, Weizman A, Chilton M, Arnold DS, Mastropaolo J.

Isr J Psychiatry Relat Sci. 2005;42(1):33-44. Review.

13.

The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.

Feuerbach D, Lingenhoehl K, Olpe HR, Vassout A, Gentsch C, Chaperon F, Nozulak J, Enz A, Bilbe G, McAllister K, Hoyer D.

Neuropharmacology. 2009 Jan;56(1):254-63. doi: 10.1016/j.neuropharm.2008.08.025. Epub 2008 Aug 28.

PMID:
18793655
14.

Assessment of auditory sensory processing in a neurodevelopmental animal model of schizophrenia--gating of auditory-evoked potentials and prepulse inhibition.

Broberg BV, Oranje B, Glenthøj BY, Fejgin K, Plath N, Bastlund JF.

Behav Brain Res. 2010 Dec 1;213(2):142-7. doi: 10.1016/j.bbr.2010.04.026. Epub 2010 Apr 24.

PMID:
20417666
15.

Prenatal choline and the development of schizophrenia.

Freedman R, Ross RG.

Shanghai Arch Psychiatry. 2015 Apr 25;27(2):90-102. doi: 10.11919/j.issn.1002-0829.215006. Review.

16.

Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazolemethanol (JNJ-1930942), a novel positive allosteric modulator of the {alpha}7 nicotinic acetylcholine receptor.

Dinklo T, Shaban H, Thuring JW, Lavreysen H, Stevens KE, Zheng L, Mackie C, Grantham C, Vandenberk I, Meulders G, Peeters L, Verachtert H, De Prins E, Lesage AS.

J Pharmacol Exp Ther. 2011 Feb;336(2):560-74. doi: 10.1124/jpet.110.173245. Epub 2010 Nov 17.

17.

P50 sensory gating in infants.

Ross AS, Hunter SK, Groth MA, Ross RG.

J Vis Exp. 2013 Dec 26;(82):50065. doi: 10.3791/50065.

19.

Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.

Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobsen EJ, Wolfe ML, Groppi VE, Hanchar AJ, Thornburgh BA, Cortes-Burgos LA, Wong EH, Staton BA, Raub TJ, Higdon NR, Wall TM, Hurst RS, Walters RR, Hoffmann WE, Hajos M, Franklin S, Carey G, Gold LH, Cook KK, Sands SB, Zhao SX, Soglia JR, Kalgutkar AS, Arneric SP, Rogers BN.

J Med Chem. 2006 Jul 13;49(14):4425-36.

PMID:
16821801
20.

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.

Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R.

Arch Gen Psychiatry. 2006 Jun;63(6):630-8.

PMID:
16754836

Supplemental Content

Support Center